Arcturus Therapeutics Holdings (ARCT) Cash from Financing Activities (2018 - 2026)

Arcturus Therapeutics Holdings has reported Cash from Financing Activities for 9 years, with the latest figure at $16000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 99.89% year-over-year to $16000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.8 million (down 109.75% YoY), and the FY2025 full-year result was $13.4 million, up 146.99% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $16000.0, down from $11.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $21.8 million in Q3 2023, with the low at -$27.4 million in Q1 2023.
• Historically, Cash from Financing Activities has averaged -$478235.3 across 5 years, with a median of $257000.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 8244.05% — and 2025, when it soared 8622.39%.
• Arcturus Therapeutics Holdings' Cash from Financing Activities stood at -$2.2 million in 2022, then slumped by 735.89% to -$18.7 million in 2023, then soared by 100.72% to $134000.0 in 2024, then soared by 8622.39% to $11.7 million in 2025, then slumped by 99.86% to $16000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $16000.0 (Q1 2026), $11.7 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.